The Fertility Boom: Why 42% of Biopharma Views It as the Top Commercial Opportunity

42% of life sciences respondents identify Fertility as the women's health area offering the greatest commercial opportunity over the next five years.

Boston MA -- October 7: While investment continues across a broad range of conditions, fertility remains a major area of focus for product development, investment, and innovation activity.

The Women's Health Infrastructure Report 2026 indicates that fertility leads the next wave of commercial opportunity, decisively outperforming maternal health, menopause, and cardiovascular health.

The distribution of responses highlights the breadth of opportunity across the women's health landscape. While fertility leads the forecast, maternal health (30%), menopause (16%), and cardiovascular health (10%) all attracted significant interest, reinforcing the growing maturation and diversification of the market beyond any single condition area.

"Cardiology has historically lagged behind obstetrics in advancing women's health in part because obstetrics is inherently focused on the biology and health of females while cardiovascular medicine cares for patients across the sex spectrum... Increasing the number and influence of women in cardiovascular medicine is therefore not simply an issue of workforce equity; it helps ensure that the right questions about women's cardiovascular health are asked, studied, and ultimately translated into better care."

Dr Malissa Wood

Chief Medical Officer, Women As One

This finding represents just one of dozens of insights uncovered through the Women's Health Infrastructure Report 2026, a cross-sector study bringing together perspectives from health plans, providers, employers, clinicians, life sciences organisations and innovators.

The full report features detailed findings, expert commentary, benchmark data and practical implications for healthcare leaders looking to understand where women's health is heading next.

Lead Research Partner